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Atherosclerosis and its late sequels are still the number one cause of death in western
societies. Platelets are a driving force not only during the genesis of atherosclerosis,
but especially in its late stages, as evidenced by complications such as arterial
thrombosis, myocardial infarction, and ischemic stroke. Atherosclerosis is increasingly
recognized as an inflammatory disease, influenced by various immune mechanisms.
The complement system is part of our innate immune system, and its diverse roles
in atherosclerosis have become evident over the past years. In this review we identify
points of intersection between platelets and the complement system and discuss their
relevance for atherosclerosis. Specifically, we will focus on roles for platelets in the onset
as well as progression of the disease, a possible dual role for complement in the genesis
and development of atherosclerosis, and review emerging literature revealing previously
unrecognized cross-talk between platelets and the complement system and discuss its
possible impact for atherosclerosis. Finally, we identify limitations of current research
approaches and discuss perspectives of complement modulation in the control of the
disease.
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INTRODUCTION
Despite remarkable progress in therapy, atherosclerosis and its
associated complications such as coronary heart disease are still
the leading cause of death in western societies (Ross, 1999).
Atherosclerosis is defined as the process of plaque formation and
stenosis in arterial vessels. Deleterious effects of plaque rupture
include acute vessel occlusion and thromboembolic complica-
tions such as myocardial infarction resulting from thrombotic
occlusion of an epicardial vessel or stroke resulting from carotid
artery plaque formation.
A complex interplay between hemostatic and inflammatory
cues is increasingly unraveled and recognized to drive the gene-
sis and exacerbations of atherosclerosis. Platelets are thought to
play a dual role here, mediating the often serious clinical effects
of plaque rupture in established atherosclerosis, but also impact-
ing the early development of atherosclerosis (Massberg et al.,
2002). The classical function of platelets is coverage and closure
of endothelial wounds, and contact between platelets and the
subendothelial matrix triggers their activation and drives throm-
bus formation also during the early pathophysiological process
of plaque formation (Figure 1). Moreover, platelets have been
shown to also interact with intact endothelium and recruit leuko-
cytes even before an atherosclerotic plaque has formed (Massberg
et al., 2002).
On the other hand, atherosclerosis is recognized as an inflam-
matory disease (Ross, 1999), making the immune system a focus
of interest. The complement system, as part of our immune sys-
tem, has important protective functions in immune defense but
can also be a driving force behind the pathological processes
of chronic inflammatory diseases (Walport, 2001). The comple-
ment system consists of a series of plasmatic proteins (zymogens)
that form enzymatic cascades, which produce a broad spectrum
of immune-active molecules and pro-inflammatory mediators
(Verschoor and Carroll, 2004). Besides these classical functions
of immune defense, the complement system also directs central
homeostatic and pathophysiological processes such as angio-
genesis, tissue regeneration, the removal of immune complexes,
apoptotic cells, and cellular debris (Ricklin et al., 2010). Thus,
with respect to atherosclerosis complement may exert proathero-
genic as well as atheroprotective effects, for which we will discuss
the evidence below in detail.
PLATELETS AND ATHEROSCLEROSIS
Platelets have a well-recognized contribution to the late throm-
botic complications associated with atherosclerosis, making them
a potent target for the development of diagnostic and therapeutic
tools (Gawaz et al., 2008). In addition, platelets can also inter-
act with endothelial cells before an atherosclerotic plaque has
formed and may thus play a role in the genesis of atheroscle-
rosis (Gawaz et al., 2005). Indeed, platelets of atherosclerotic
apolipoprotein E deficient (ApoE–/–) mice were observed to
adhere to intact endothelium via the von Willebrand factor
receptor GPIbα and the fibrinogen receptor GPIIbIIIa well before
atherosclerotic plaques had formed (Massberg et al., 2002; Huo
et al., 2003; Gawaz et al., 2005). Still, absence of GPIIbIIIa alone
does not fully protect from atherosclerosis, as is known from
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FIGURE 1 | Upper part: Model of platelet interaction with the damaged
vessel wall: exposure of subendothelial matrix after endothelial lesion
leads to platelet tethering, activation and accumulation to provide sealing
of the endothelial wound. Lower part: Model of platelet interaction with
the endothelium. Platelets interact with the endothelium via adhesion
receptors such as GPIbα and PSGL-1 promoting rolling and subsequent
firm adhesion via β3 integrins. Interaction with endothelial bound
chemokines such as Cx3CL1 (fractalkine) or CCL5 (Rantes) results in
P-Selectin mediated recruitment of leukocytes to the vessel wall and
subsequent transmigration. For both interaction with the subendothelial
matix and the endothelium, major adhesion receptors expressed on
platelets are listed.
studies assessing patients with Glanzmann thrombasthenia whose
platelets lack functional GPIIbIIIa. Indeed, ultrasound imaging
of the carotid bifurcation of such patients revealed plaques in
4 of 7 individuals (Shpilberg et al., 2002). Therefore, platelet-
vessel wall interactions via GPIIbIIIa may contribute to, but do not
seem to be a prerequisite in the genesis of human atherosclerosis
and may be functionally substituted by other platelet recep-
tors. Mice with deficiency in GPIbα are not protected from
atherosclerotic plaque formation (Strassel et al., 2009). On the
other hand, platelet depletion with a GPIbα-specifc antibody
in ApoE–/– mice leads to reduced leukocyte accumulation in
the arterial intima and attenuated atherosclerotic plaque for-
mation, importantly indicating that adhering platelets form a
focal point for the immune-cell driven inflammation that typ-
ifies atherosclerosis (Massberg et al., 2002). Indeed, PSGL-1 or
GPIbα allow platelets to interact with P-selectin expressed on
intact endothelium. This initial “rolling” interaction is followed
by β3 integrin–mediated firm “adhesion” of platelets to the
vessel wall (Gawaz et al., 2005), and these events are seen as
crucial steps in the initiation of atherosclerosis. Platelets express
various inflammatory receptors, including fractalkine receptor
(CX3CR1) which induces P-selectin on platelets upon binding
to fractalkine (CX3CL1) expressed on inflamed endothelial cells
(Schulz et al., 2007). In turn, P-selectin exposure initiates local
accumulation of leukocytes, driven by arterial shear forces (Schulz
et al., 2007) (Figure 1). The importance of P-selectin in the gen-
esis of atherosclerosis is underlined by the finding of increased
intima-media-thickness in human subjects presenting with high
levels of platelet P-selectin (Koyama et al., 2003). Indeed, both
platelet and endothelial P-selectin contributed to lesion forma-
tion in a mouse model of atherosclerosis that was based on
the adoptive transfer of P-selectin positive or negative platelets
(Burger and Wagner, 2003).
Whether platelet-adhesion to the intima mediates direct dam-
age to the endothelial lining remains unclear, but several studies
found how platelets contribute to vascular inflammation via their
interaction with leukocytes (Santoso et al., 2002; Schober et al.,
2002; Langer et al., 2007, 2012; Ley et al., 2007; Langer and
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Chavakis, 2009). Activated platelets were shown to exacerbate
atherosclerosis in ApoE deficient mice via the recruitment of
monocytes and other leukocytes (Wagner and Frenette, 2008; von
Hundelshausen et al., 2009). In turn, the formation of platelet-
leukocyte aggregates (PLA) facilitated the deposition of inflam-
matory platelet mediators on endothelial cells (Schober et al.,
2002; Huo et al., 2003). Others found that the number of circu-
lating PLAs is increased upon platelet activation (van Gils et al.,
2009; Totani and Evangelista, 2010). As potential mechanisms
underlying platelet-leukocyte crosstalk, several receptor/ligand
pairs have been identified, including integrins or members of
the JAM family of proteins (von Hundelshausen and Weber,
2007; Wagner and Frenette, 2008; von Hundelshausen et al.,
2009). A list of platelet expressed receptors with potential rel-
evance for artherosclerosis is given in Table 1. Finally, platelets
may also contribute to vascular inflammation via release of active
biomolecules from their granules (Langer and Gawaz, 2008;
Patzelt and Langer, 2012). As prominent examples, the release of
chemokines such as CCL5 or CXCL4 contributes to atheroscle-
rosis in a P-selectin dependent manner (von Hundelshausen and
Schmitt, 2014).
Given the relevance of fatty acids in the genesis of artheroscle-
rosis, it should be noted that also oxidized LDL—one of the
major initiators and drivers of atherosclerosis—can be bound by
platelets and interactions with lipoproteins can change platelet
function (Siegel-Axel et al., 2008; Stellos et al., 2012). In line
with this, platelets of hypercholesterolemic patients show hyper-
aggregability in vitro and enhanced activity in vivo (Cipollone
Table 1 | Platelet receptors, their ligands, and their target structure
contributing to vascular inflammation.
Receptor Ligand Interaction with
PSGL-1 P-Selectin Endothelial cells (Frenette et al.,
2000)
P-Selectin PSGL-1 Leukocytes (Dole et al., 2007)
GPIbα Mac 1
P-Selectin
Leukocytes (Gawaz et al., 1997)
Endothelial cells (Massberg
et al., 2002)
GPIIb-IIIa (αIIbβ3) Mac 1
Fibrinogen, vWF
Leukocytes (Weber and Springer,
1997)
Vessel wall (Bombeli et al., 1998)
α5β1,α6β1 Subendothelial
extracellular matrix
Damaged vessel wall (Gruner
et al., 2003)
α2β1 Collagen Damaged vessel wall (Inoue
et al., 2003)
αVβ3 Vitronectin Endothelial cells (Gawaz et al.,
1997)
CX3CR1 CX3CL1 Endothelial cells (Schulz et al.,
2007)
ICAM-2 LFA-1 Leukocytes(Weber et al., 2004)
JAM-A JAM-A Vessel wall (Karshovska et al.,
2015)
JAM-C MAC-1 Dendritic cells (Langer et al.,
2007)
GPVI Collagen Damaged vessel wall (Massberg
et al., 2003)
et al., 2002; Ferroni et al., 2006). In conclusion, platelet activation
seems to confer proatherosclerotic effects, as well as effects of
atheromodulation and tissue/vascular remodeling.
THE COMPLEMENT SYSTEM AND ATHEROSCLEROSIS
As noted earlier, many cells and molecular mediators that were
identified to modulate the development of artherosclerosis are
components of the immune system. Complement, as part of the
innate immune system, has a broad range of immune-modulatory
effects, including the opsonization of microbial intruders with
C1q or manose binding lectin (MBL), followed by the activa-
tion products of C2, C3, and C4 (including the opsonins C3b
and C4b), the induction of mast cell degranulation via soluble
anaphylatoxins C3a and C5a and the attraction of inflammatory
cells (Verschoor and Carroll, 2004). Components C5b–C9 form
the membrane attack complex (MAC), which mediates lysis of
target cells. Beyond immune defense, the complement system
directs central homeostatic and pathophysiological processes in
tissue remodeling and the removal of immune complexes, apop-
totic cells and cellular debris (Ricklin et al., 2010). Components
of the classical pathway, including C1q, C2, and C4, are asso-
ciated with the homeostatic control of such complexes, as their
deficiency predisposes to diseases characterized by an impair-
ment in the removal of cellular remnants, for example known
in Systemic Lupus Erythomatosis (SLE) (Aggarwal et al., 2010).
Apoptotic and necrotic cells also accumulate in atherosclerotic
plaques, and a Swedish study identified a significant associa-
tion between genetic C2 deficiency and atherosclerosis, including
a higher rate of myocardial infarctions and stroke in a cohort
of 40 patients (Jonsson et al., 2005). Furthermore, in patients
with the premature atherosclerotic peripheral vascular disease C4
deficiency, a significant proportion of diseased patients revealed
circulating immune complexes and their enhanced propensity to
immune complex formation was associated with a higher preva-
lence of circulating immune complexes in atherosclerotic patients
(Nityanand et al., 1999). A genome-wide analysis found a SNP of
C1q receptor C1qRp (CD93) constituting a risk factor for coro-
nary artery disease, which could be confirmed in patients with
familial hypercholesteremia (van der Net et al., 2008) and poly-
morphisms for mannose binding lectin (MBL) with decreased
levels of the protein went along with more coronary artery disease
and increased carotid plaque (Madsen et al., 1998; Hegele et al.,
2000; Best et al., 2004).
Complement activation also promotes inflammation, through
the generation of anaphylatoxins. Analyzing circulating levels of
such complement components demonstrated that patients with
advanced atherosclerosis present with elevated levels of ana-
phylatoxin C5a, predictive of major cardiovascular events and
independent of known risk markers such as C reactive protein
(CRP) or fibrinogen (Speidl et al., 2005).
Complement factors have been detected in substantial
amounts within atherosclerotic plaques (Laine et al., 2002; Speidl
et al., 2011a). Under normal conditions, activated complement
components are quickly cleared from the circulation. However,
activated complement and the MAC were identified within fatty
streaks (early stages of plaque formation, before the arrival
of inflammatory cells) in cholesterol-fed rabbits (Seifert et al.,
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1989). This finding was confirmed by following studies, which
demonstrated the presence of the terminal complement complex
C5b–9 in human atherosclerotic arteries (Niculescu et al., 1985,
1987; Torzewski et al., 1998).
Such complement components may derive from the blood cir-
culation (Vlaicu et al., 1985; Niculescu and Rus, 2004), but the
presence of mRNA for several complement components (includ-
ing C1r, C1s, C4, C7, and C8) indicates that these factors also
may be produced locally within the plaque (Yasojima et al.,
2001; Niculescu and Rus, 2004). Indeed, various studies iden-
tified the power of local complement production (as opposed
to circulating systemic complement) in driving immune pro-
cesses (Verschoor et al., 2001, 2003; Gadjeva et al., 2002; Li
et al., 2007). Interestingly, complement activation differs between
superficial and deeper layers of the atherosclerotic plaque: in the
luminal layer, signs of classical and alternative, but not termi-
nal, complement activation can be found, consistent with the
local presence of complement regulators C4bp and fH (Oksjoki
et al., 2003, 2007). In contrast, terminal complement complex
deposition is detected in the deeper layers of the intima, asso-
ciated with smooth muscle cells, cell debris, and extracellular
lipids (Oksjoki et al., 2003, 2007) (Figure 2). In addition, C1q
and the receptor for its globular domain (gC1q-R) are found in
the necrotic core of advanced atherosclerotic lesions (Peerschke
et al., 2004). Also C3b can be detected, with stronger deposition in
ruptured compared to non-ruptured plaques of the same patients
(Laine et al., 2002). Another sign of increased complement acti-
vation within ruptured plaques is the significantly higher C5a
concentration associated with lipid-rich inflammatory lesions
containing exposed cholesterol and necrotic cell debris than
with stable plaques containing collagen- and elastin (Speidl
et al., 2011b). Epidemiological data underline this notion and
show increased C5a levels in patients with increased cardio-
vascular disease risk, independent of non-specific inflamma-
tory markers such as C-reactive protein (CRP) or fibrinogen
(Speidl et al., 2005). Also elevated C4 levels in the circula-
tion are associated with severe atherosclerosis (Muscari et al.,
1988). Still, mere detection of complement activation or depo-
sition does not yet ascertain a deleterious or a protective role
for the complement system in artherosclerosis. In fact, vari-
ous studies underline a pro-atherosclerotic role of complement,
while others suggest protective effects for complement. Already
in the late 1970s Geertinger et al could show that C6 deficiency,
for instance, protects cholesterol-fed rabbits from atherosclero-
sis (Geertinger and Sorensen, 1970) and inhibition of C5a or its
receptor C5aR1 (CD88) reduces atherosclerosis in murine mod-
els (Shagdarsuren et al., 2010; Manthey et al., 2011). On the
other hand, C1q deficiency leads to the development of signif-
icantly larger lesions in atherosclerotic low-density lipoprotein
receptor deficient (LDLR–/–) mice compared to C1q-sufficient
controls (Bhatia et al., 2007; Lewis et al., 2009). One explanation
for this observation may be that C1q binds apoptotic or necrotic
cells in plaques directly (or indirectly via IgM), facilitating their
removal by macrophages by promoting classical pathway deposi-
tion of C3 activation products. Indeed, C3 deficiency promotes
the development of larger abdominal and thoracic aorta lesions
in atherosclerotic LDLR–/– mice than in C3-sufficient controls.
The aortic root lesions of the C3-deficient mice showed increased
FIGURE 2 | Complement activation within the atherosclerotic plaque. TCC, terminal complement complex; C3, C3a, C4bp, different components of the
complement cascade; fH, factor H.
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lipid and macrophage deposition, combined with decreased col-
lagen and smooth muscle cell content, indeed suggesting a net
protective effect for C3 in this model (Buono et al., 2002). This
notion is underlined by the fact that mice lacking both ApoE and
LDLR show a dramatically increased aortic lesions load (+84%)
when C3 is absent too (Persson et al., 2004). Given the ambigu-
ous experimental findings regarding the role of complement in
the genesis of artherosclerosis, the efficacy of targeting comple-
ment in coronary artery disease (CAD) was directly assessed in
several clinical trials. Consistent with the protective effects seen in
experimental studies interfering with C5 function (Manthey et al.,
2011; Shagdarsuren et al., 2010), treatment with anti-C5 anti-
body (Pexelizumab) resulted in significantly reduced mortality
in ST-elevated myocardial infarction (STEMI) patients (Granger
et al., 2003). Other trials that examined complement inhibition in
patients undergoing coronary artery bypass graft surgery found
positive effects on morbidity and mortality (Testa et al., 2011).
All in all, a heterogeneous picture emerges regarding the role of
complement in atherosclerosis and also open questions remain
(Figure 3), which will have to be addressed in future basic and
clinical studies to further define the role of complement and its
potential and perspective for targeted treatment of atherosclerosis
patients.
PLATELETS AND THE COMPLEMENT SYSTEM
Given the association of platelets and the complement system
with the genesis and late complications of atherosclerosis, as well
as their intimate contact in the circulation, a closer review of
their interactions is warranted. A wide variety of complement
factors and receptors have been identified in platelet isolates
(Hamad et al., 2010). We recently found that the expression
of anaphylatoxin-receptors (C3aR and C5aR) and activation
markers (i.e., P-selectin) on platelets correlates with CAD in
patients (Patzelt et al., 2014). Others described a potentially self-
reinforcing cycle, in which complement can activate platelets and,
in turn, thrombin activated platelets are able to initiate the com-
plement cascade (Hamad et al., 2008). In addition, CR4, also
a receptor for iC3b, is expressed on platelets but so far with
unclear function (Vik and Fearon, 1987). Besides the aforemen-
tioned C3-fragment receptors, platelet expressed C1q receptors
gC1qR/p33 and cC1qR were shown to mediate platelet aggre-
gating and activating effects (Wautier et al., 1977; Peerschke and
Ghebrehiwet, 1997, 2001). Also receptors for anaphylatoxins C3a
and C5a, which are generated further downstream in the com-
plement activation cascade, are found on platelets. C3a and its
derivative C3a-des-Arg induce platelet activation and aggregation
in vitro (Polley and Nachman, 1983; Martel et al., 2011).
The intimate contact between platelets and plasma proteins,
including complement, combined with the propensity of platelets
to become activated by complement, requires that platelets
actively counteract complement deposition onto their surface. To
this end, platelets express and bind a variety of complement con-
trol proteins (CCPs) on their membrane (Verschoor and Langer,
2013). Indeed, absence or impairment of function of such CCPs
is associated with platelet dysfunction, and activation thrombocy-
topenia, again underlining the potential of the complement sys-
tem to influence platelet physiology and function (Verschoor and
Langer, 2013). In atypical hemolytic uremic syndrome (aHUS),
deficiencies or mutations in CCPs, frequently in factor H, may
result in excessive complement activation on platelets, leading to
thrombocytopenia and prothrombotic complications (Stahl et al.,
2008). Another immune mediated pathology in which platelets
are affected by overwhelming complement activation is paroxys-
mal nocturnal hemoglobinuria (PNH). Here, a mutation in the
FIGURE 3 | Consequences of complement activation: complement
interacts with inflammatory cells, may, however, also have a
functional relationship with platelet activation. Via promotion of
inflammation, complement contributes to the formation of the fatty
streak, under distinct conditions, however, atheroprotective effects can
not be excluded.
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phosphatidylinositol glycan A (PIGA) enzyme prevents the effec-
tive anchoring of CCPs decay-accelerating factor (DAF, CD55)
and protectin (CD59) to the platelet surface (Nicholson-Weller
et al., 1982). With the advent of Eculizumab, a humanized ver-
sion of the anti-C5 antibody h5G1.1, which was first described in
1996, both conditions can now be effectively treated. Eculizumab
is a drug approved for the treatment of PNH. By binding directly
to C5, this mAb prevents the cleavage of C5–C5b and, thus, sup-
presses the formation of the membrane damaging MAC (Thomas
et al., 1996).
Finally, platelets may also interact with the complement sys-
tem via proteins that are not considered classical complement
receptors, such as P-selectin (Del Conde et al., 2005) or GP1bα
(Verschoor et al., 2011). In the case of P-selectin it was observed
that it can bind C3b and mediate the generation of C3a and
MAC formation (Del Conde et al., 2005). As exemplified by
the pathology and treatment of aHUS and PNH, platelet acti-
vation is enhanced by MAC formation causing a prothrombotic
state (Sims and Wiedmer, 1991). In the case of GPIbα, bacterial
infection studies in mice revealed that, upon systemic infection,
C3b-opsonized bacteria form complexes with platelets in the
bloodstream. Such complexes can only form in the presence of the
alpha chain of GPIb on the platelet surface, strongly suggesting
that GPIb directly or indirectly interacts with activated comple-
ment C3 (Verschoor et al., 2011). Interestingly, both GPIb and
C3 deficient mice show prolonged bleeding times (Strassel et al.,
2007; Gushiken et al., 2009), strengthening the notion that these
molecules may synergize in physiological hemostatic processes.
PERSPECTIVE AND OUTLOOK
Various clinical and experimental lines of evidence indicate that
platelets and the complement system influence the initiation
and pathogenesis of atherogenesis and modulate each other’s
function. While clinical evidence is mounting, most of our mech-
anistic understanding of atherosclerosis still derives from animal
models which model some, but not all characteristics of human
atherosclerosis. With non-invasive methods lacking, our ability
to directly assess the mechanisms, pathophysiology and plaque
burden of human atherogenesis remains limited and indirect
parameters (i.e., intima-media thickness, CT-based coronary cal-
cium, mortality) have to be used instead. While such parameters
are important in terms of practical patient care, it is often difficult
to assess, whether i.e., anti-platelet treatment works by reducing
atherosclerotic lesions or by preventing the thrombotic complica-
tions of plaque rupture. Thus, such studies unfortunately remain
limited in helping us understand the underlying mechanisms. We
therefore believe that, in addition, a hypothesis-driven approach
is needed to bring seemingly disparate mechanisms in atheroscle-
rotic lesion development together, as we attempt here in this
review with complement and platelets.
Several studies show that activated complement is more abun-
dant in unstable plaques than in stable atherosclerotic lesions.
Underlining the notion that complementmay have long remained
an underestimated factor in artherosclerosis is provided by recent
clinical studies that show that pexelizumab, a humanized mono-
clonal antibody against C5, clearly reduced rates of acute major
cardiac events after STEMI or coronary bypass surgery (Granger
et al., 2003; Verrier et al., 2004). Nonetheless, the drug failed
to reduce mortality or recurrent myocardial infarction in the
large, randomized controlled APEX AMI trial (Investigators et al.,
2007).
Thus, the mixed results highlight once more the complexity
of the pathological mechanisms underlying artherosclerosis and
the need for intensified clinical and experimental studies prob-
ing the interaction of complement and platelets in the context of
atherosclerosis. It stresses the need for a comprehensive approach,
combining both clinical and experimental research, to uncover
and detail further links between platelets and complement with
the aim to identify new and promising pharmacological targets in
the treatment of atherosclerosis.
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